Camurus’ FluidCrystal technology is designed for long-acting drug release to provide treatment efficacy over extended periods – from days to months – with a single injection. It has the potential to reduce the burden of daily medication while increasing adherence to therapy.

The system’s simplicity, including a spontaneous self-association to a functional structure in the body, eliminates complicated manufacturing procedures and the need for mixing prior to administration. Medicines based on the FluidCrystal technology have the potential to be administered by the patients themselves or by healthcare professionals, without time-consuming and complicated reconstitution procedures. The long-acting release aims to reduce the patient’s burden of administering medication daily, improve the adherence to and results of the treatment, and improve the patient’s quality of life.

Mode of action

The FluidCrystal technology comprises a lipid-based liquid with a dissolved active ingredient that can easily be injected subcutaneously using a conventional syringe with a thin needle or injection pen. Upon contact with fluids in the tissue, the lipid solution transforms into a liquid crystalline gel, which effectively encapsulates the active ingredient. The medicinal compound is slowly released as the liquid crystalline matrix gradually degrades in the tissue and the release can be controlled from several days to weeks or months depending on the composition. FluidCrystal is suitable for both small molecules, peptides and proteins. 

Applications of FluidCrystal in medical treatment

Camurus’ FluidCrystal technology has been validated trough more than 25 clinical trials and several market approvals, including the Camurus’ product Buvidal® (buprenorphine) prolonged-release solution for the treatment of opioid dependence. FluidCrystal is commercially well-tested and at the end of 2023, more than two million doses of FluidCrystal-based products and product candidates had been administered to patients around the world.